Skip to content

Management of Cancer Therapy Related Vulvovaginal Atrophy

Comparison Between Platelet-rich Plasma (PRP) and Hyaluronic Acid (HA) in the Treatment of Cancer-therapy Related Vulvovaginal Atrophy and Its Impact on Sexual Satisfaction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05782920
Enrollment
45
Registered
2023-03-24
Start date
2020-06-30
Completion date
2021-03-31
Last updated
2023-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary Syndrome of Menopause

Brief summary

The goal of this clinical trial is to: 1. evaluate the efficacy of PRP injection and PRP injection mixed with non-cross-linked hyaluronic acid compared to the control group receiving standard therapy with topical non-cross-linked hyaluronic acid gel in the treatment of cancer therapy-induced or worsened vulvovaginal atrophy. 2. To evaluate the impact of vulvovaginal atrophy treatment on the sexual satisfaction of both partners. Patients will be divided randomly into 3 groups: Group 1: 15 female patients will receive vaginal PRP injections. Group 2: 15 female patients will receive vaginal PRP injections combined with non-cross-linked hyaluronic acid. Group 3: 15 female patients will receive topical non-cross-linked hyaluronic acid gel as a control group.

Detailed description

1. The first group will receive two treatment of sub-mucosal PRP injection at the outer 3 cm of the vagina with one month interval in between. (17) 2. The second group will receive two treatment of PRP injection mixed with non-cross linked hyaluronic acid at the outer 3 cm of the vagina with one month interval in between. 9\. 3-The third group will receive one applicator (5gm) three times per week of topical hyaluronic acid gel for vaginal application which will be prepared in the faculty of pharmacy for 2 months. Clinical assessment Patients will be assessed for symptoms and signs of vulvovaginal atrophy (VVA) at baseline, one month, two months, and, three months after the end of treatment. 1. Vulvovaginal atrophy (VVA) symptoms (dryness, dyspareunia) will be assessed on a subjective 10-point scale. Also, patient satisfaction with each type of treatment will be assessed with a questionnaire at the end of treatment and they will be asked if they wish to repeat the treatment to maintain effectiveness over time (yes or No). 2. For assessment of VVA signs on physical examination, vaginal health index including assessment of pH, overall elasticity, epithelial mucosa, fluid secretion type, and consistency and moisture will be used as an objective method of evaluation of therapy. 3. Assessment of sexual satisfaction of both male and female partners: Sexual satisfaction was measured using the Arabic version of the Index of Sexual Satisfaction (ISS) and female sexual function index (FSFI) questionnaire.

Interventions

DEVICEPlatelet rich plasma

PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.

DEVICEnon cross-linked hyaluronic acid

HA filling is a known modality for rejuvenation

DEVICEtopical HA gel

the standard treatment of vaginal atrophy and dryness

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients have symptoms of VVA (vaginal dryness, burning, itching or dyspareunia) * Patients with vaginal health index \< 15. * All patients have already finished cancer therapy or are on anti-estrogen treatment. * Married sexually active * Patients who are not receiving any VVA treatment for at least 30 days before starting therapy.

Exclusion criteria

* Active or recent history of vulvovaginal inflammation or infection * History of vulvar or vaginal cancer. * Suspicious lesion in the vulvovaginal area on the gynecological examination

Design outcomes

Primary

MeasureTime frameDescription
Vulvovaginal atrophy vaginal dryness severity scoresbefore treatmentscores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms
Vulvovaginal atrophy dyspareunia severity scoresbefore treatmentscores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms
Vaginal health index total scorebefore treatmentscores range from 5-25 with lower scores signifying greater atrophy

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026